1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
683CB1E589984285E00258AEE0023B261
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-establishing-north-america-standards-field-medical-performance-excellence?opendocument
18
19opendocument
2034.239.151.124
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing North America Standards for Field Medical Performance Excellence

ID: 5799


Features:

11 Info Graphics

30 Data Graphics

410+ Metrics

21 Narratives


Pages/Slides: 47


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing North America Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

To achieve excellence in the dynamic North American market, biopharma manufacturers must focus on enhancing the capabilities of their field medical teams. This entails understanding key performance metrics, competitor frameworks, and strategies for effective engagement with stakeholders.

Best Practices, LLC conducted benchmarking research tailored for North America, aiming to aid Field Medical Excellence leaders in crafting a robust framework for excellence. The study delivers strategic insights to enrich KOL interactions, evaluate MSL performance, and strategically align staffing footprints. By addressing these critical topics, our study equips Field Medical Excellence leaders with the necessary knowledge and tactics to drive field medical performance excellence across North America. Leveraging a robust dataset, the study further provides segmented insights at the country level, offering valuable benchmarks for the United States and Canada.


KEY TOPICS

  • Effective Field Performance Metrics in North America
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in North America
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • North America Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in North America

KEY METRICS

  • Average total panel size supported by an individual MSL across North America, including separate figures for the United States and Canada
  • Average number of monthly KOL/HCP and F2F meetings in North America, with specific data for both the United States and Canada
  • Average time spent in KOL interactions in North America, along with separate figures for the United States and Canada
  • Value assigned to each interaction type on the MSL scorecard across North America, with individual breakdowns for the United States and Canada
  • Optimal and widely utilized field metrics for assessing and showcasing MSL impact across North America, with details for both the United States and Canada
  • Engagement metrics for non-tiered KOLs in North America, covering both the United States and Canada, with separate metrics for each country
  • Average annual field presence of MSLs across North America, including separate figures for the United States and Canada
  • Time spent by MSLs on external, internal, and logistics activities in North America, with separate breakdowns for the United States and Canada
  • Weekly MSL time allocation across activity streams in North America, with specific data for both the United States and Canada
  • MSL engagement mix across North America, including separate breakdowns for the United States and Canada
  • Field medical staffing footprint across North America, with separate figures provided for the United States and Canada
  • Span of control: Number of MSLs per MSL manager across North America, with separate data for the United States and Canada

SAMPLE KEY FINDINGS

  • North America Span of Control (MSLs per Manager): The United States exhibits a leaner span of control, with an average of 7 MSLs per manager, compared to Canada, where the average is 5 MSLs per manager.

METHODOLOGY

This study offers tailored benchmarks and insights focused on North America. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from over 100 biopharma manufacturers across the world. The data is meticulously segmented at both regional and country levels to offer nuanced insights.


Additionally, Best Practices, LLC utilizes its proprietary Field Medical Excellence database to provide additional benchmarks tailored to align with varied portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.